Dr. MacKenzie and her team at UCSF are using hematopoietic stem cells (HSCs) to treat babies in the womb who have alpha thalassemia major, a blood disorder that is almost always fatal. Current…
Age-related macular degeneration is a progressive disease resulting in death of the retinal pigment epithelium (RPE) causing distortion to central vision and eventually to legal blindness. Regenerative Patch Technologies and…
There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient's own immune system…
Geron carried out a Phase 1 clinical trial to assess the safety and preliminary activity of escalating doses of human embryonic stem cell (hESC) derived oligodendrocyte progenitor cells for treatment…
Angiocrine is developing a cell therapy aimed to improve the availability and engraftment of blood stem cell transplants for cancer patients who have had their cancerous bone marrow removed by chemotherapy.…
Forty Seven Inc. is conducting a Phase 1b clinical trial for acute myeloid leukemia patients. Leukemia stem cells have a protein on their surface that enable them to evade being…
A team at the City of Hope led by Dr. Christine Brown is pursuing a Phase 1 trial targeting an aggressive brain cancer called malignant glioma. City of Hope will…
To help improve accessibility to eligible CIRM patients This project will allow patients in underserved communities in California equal access to clinical trials without bias due to financial circumstances.
Therapeutic Candidate or Device The therapeutic candidate is COVID-19 convalescent plasma (CCP) Indication The target indication is treatment of severe COVID-19 infection Therapeutic Mechanism Neutralizing antibodies are part of the…
Therapeutic Candidate or Device CRISPR corrected blood stem cells are manufactured from persons with severe sickle cell disease and returned by transplant to the same person Indication Persons with sickle…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
